NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

WINT

Windtree Therapeutics Inc

Jun 30 • 04:00PM ET

0.5161

Dollar change +0.0666
Percentage change 14.82	%

Healthcare • Biotechnology • USA • NASD

Peers: AGIO INVA LPCN BLRX APTO ALT XOMA VRNA SCPH TFFP

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1261.32	Insider Own	0.08%	Shs Outstand	3.56M	Perf Week	29.02%
Market Cap	1.89M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.75M	Perf Month	-34.67%
Enterprise Value	3.50M	PEG	-	EPS next Q	-0.11	Inst Own	6.04%	Short Float	124.02%	Perf Quarter	-66.92%
Income	-20.75M	P/S	-	EPS this Y	-	Inst Trans	363.54%	Short Ratio	0.38	Perf Half Y	-96.60%
Sales	0.00M	P/B	0.18	EPS next Y	-	ROA	-56.45%	Short Interest	0.93M	Perf YTD	-97.04%
Book/sh	2.89	P/C	1.62	EPS next 5Y	-	ROE	-120.01%	52W High	737.43 -99.93%	Perf Year	-99.68%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	90.53% 75.28%	ROIC	-175.14%	52W Low	0.36 43.36%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.86% 15.55%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	34.39%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.35	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.25	EPS Q/Q	-100.42%	SMA20	-10.38%	Beta	0.69	Target Price	4.00
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	-35.02%	Rel Volume	0.99	Prev Close	0.45
Employees	14	LT Debt/Eq	0.05	Earnings	May 16 BMO	SMA200	-97.75%	Avg Volume	2.46M	Price	0.52
IPO	Aug 08, 1995	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	2,431,674	Change	14.82%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-20	Initiated	Ladenburg Thalmann	Buy	$12.25

Jun-30-25 09:00AM	Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis (GlobeNewswire) +14.82%
Jun-26-25 04:05PM	Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel (GlobeNewswire) +23.24%
Jun-16-25 08:00AM	Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study (GlobeNewswire)
Jun-11-25 09:00AM	Windtree Receives Offer for Its Preclinical Oncology Drug Candidate (GlobeNewswire) -12.51%
Jun-10-25 08:00AM	Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business (GlobeNewswire) +43.58%
08:15AM	Loading…
Jun-09-25 08:15AM	Evofem Biosciences CEO Saundra Pelletier Joins Aditxt Board of Directors (Business Wire)
Jun-03-25 04:05PM	Windtree Announces Plan for Cryptocurrency Treasury Policy (GlobeNewswire) +5.36% -15.80%
May-22-25 08:16AM	Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 (GlobeNewswire) -5.00%
May-19-25 08:00AM	Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference (GlobeNewswire)
May-16-25 08:00AM	Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates (GlobeNewswire)
May-12-25 08:00AM	Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 (GlobeNewswire) +6.71%
May-06-25 08:18AM	Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US (GlobeNewswire) -11.76%
May-01-25 08:30AM	Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development (GlobeNewswire) -14.53%
Apr-15-25 08:00AM	Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates (GlobeNewswire) -13.24%
Mar-26-25 08:47AM	Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics (PR Newswire)
08:30AM	Loading…
Mar-24-25 08:30AM	Evofem Reports Fourth Consecutive Year of Net Sales Growth (PR Newswire) +18.92%
08:00AM	Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules (GlobeNewswire)
Mar-20-25 08:27AM	Windtree shares rise as it announces agreement to become sourcing partner for Evofem (SeekingAlpha) +28.99%
08:00AM	Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product (GlobeNewswire)
Mar-04-25 08:00AM	Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure (GlobeNewswire) -22.68%
Feb-27-25 08:00AM	Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India (GlobeNewswire)
Feb-18-25 08:00AM	Windtree Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -20.01%
Feb-12-25 08:00AM	Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire) +6.31%
Jan-15-25 08:00AM	Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline (GlobeNewswire)
Jan-13-25 08:00AM	Windtree Announces the Addition of Leanne Kelly to Its Board of Directors (GlobeNewswire)
Jan-08-25 08:00AM	Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline (GlobeNewswire) -11.02%
Dec-16-24 08:00AM	Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference (GlobeNewswire) +11.74%
Dec-09-24 08:00AM	Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia (GlobeNewswire)
Dec-04-24 08:00AM	Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction (GlobeNewswire) -20.39%
07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
07:00AM	Loading…
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Nov-27-24 04:05PM	Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates (GlobeNewswire) +8.20% -13.00%
Nov-14-24 08:00AM	Windtree Announces Leadership Transition Plan With Industry Veterans (GlobeNewswire) -6.25%
Nov-04-24 08:00AM	Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong (GlobeNewswire)
Oct-30-24 08:00AM	Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 (GlobeNewswire) -9.50%
Oct-24-24 08:26AM	Windtree Therapeutics completes national phase filings for istaroxime (TipRanks) -5.86%
Oct-23-24 08:00AM	Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World (GlobeNewswire)
Oct-21-24 08:00AM	Windtree To Present at the ThinkEquity Conference on October 30th (GlobeNewswire) +17.16%
Oct-17-24 08:15AM	Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan (GlobeNewswire) +43.27%
Oct-09-24 08:00AM	Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design (GlobeNewswire) -18.48%
Sep-30-24 08:15AM	Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock (GlobeNewswire) -7.00%
Sep-26-24 04:05PM	Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET (GlobeNewswire) -6.55% -5.17%
Sep-25-24 08:15AM	Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire) -11.04%
Sep-04-24 08:00AM	Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Aug-20-24 04:05PM	Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates (GlobeNewswire) -6.06%
Aug-14-24 04:05PM	Windtree Announces New Additions and Changes to Its Board of Directors (GlobeNewswire) +9.11%
Jul-26-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +151.98%
Jul-25-24 08:00AM	Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data (GlobeNewswire) -10.60%
Jul-22-24 04:05PM	Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock (GlobeNewswire)
May-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +7.73%
May-07-24 08:00AM	Windtree Therapeutics Regains Compliance with Nasdaq (GlobeNewswire) -9.74%
Apr-18-24 08:00AM	Windtree Therapeutics Announces Reverse Stock Split (GlobeNewswire) -15.32%
Apr-17-24 08:00AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
06:52AM	WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Apr-08-24 04:48PM	Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing (GlobeNewswire) -9.51%
Feb-01-24 08:00AM	Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research (GlobeNewswire)
Jan-31-24 08:00AM	Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives (GlobeNewswire) -6.60%
Jan-26-24 09:20AM	Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company (ACCESSWIRE)
Jan-25-24 08:30AM	Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company (GlobeNewswire)
Jan-18-24 09:00AM	Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China (ACCESSWIRE)
Jan-17-24 08:00AM	Windtree Therapeutics Announces License Agreement with Lees Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region (GlobeNewswire) -18.04%
Jan-02-24 04:05PM	Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator (GlobeNewswire) -10.61%
Dec-19-23 09:30AM	Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024 (ACCESSWIRE)
Dec-18-23 08:00AM	Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Nov-16-23 08:00AM	Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent (GlobeNewswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 04:15PM	Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
Nov-08-23 08:00AM	Windtree to Present at the Sidoti Micro Cap Conference on November 16th (GlobeNewswire)
Oct-12-23 07:30AM	Windtree to Present at the ThinkEquity Conference on October 19th in New York City (GlobeNewswire) +18.42%
Oct-10-23 07:30AM	Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th (GlobeNewswire)
Oct-03-23 08:00AM	Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace) -7.02%
Aug-23-23 08:00AM	Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office (GlobeNewswire)
Aug-16-23 09:00AM	Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market (ACCESSWIRE)
Aug-07-23 04:05PM	Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire) +6.82%
Jul-25-23 09:25AM	Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure (ACCESSWIRE)
Jul-18-23 09:00AM	The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market (ACCESSWIRE)
Jul-14-23 09:00AM	Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That (ACCESSWIRE)
Jun-27-23 08:00AM	Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-12-23 08:00AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism (GlobeNewswire) -5.08%
Jun-05-23 08:00AM	Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones (GlobeNewswire) +8.63%
May-15-23 04:30PM	Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
May-11-23 12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey)
Apr-27-23 08:00AM	Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime (GlobeNewswire)
Apr-24-23 04:01PM	Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option (GlobeNewswire) -12.26%
Apr-20-23 08:30AM	Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering (GlobeNewswire) -57.68%
Apr-17-23 08:00AM	Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent (GlobeNewswire) +88.81%
Apr-03-23 07:35AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Mar-13-23 08:00AM	Windtree Regains Compliance with Nasdaq (GlobeNewswire)
Mar-06-23 08:00AM	Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime (GlobeNewswire)
Feb-28-23 08:00AM	Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure (GlobeNewswire)
Feb-27-23 08:00AM	Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -8.99%
Feb-24-23 08:00AM	Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office (GlobeNewswire) -15.85%
Feb-23-23 12:00PM	Windtree Therapeutics Announces Reverse Stock Split (GlobeNewswire) -34.40%
Jan-20-23 08:37AM	Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants (GlobeNewswire) -25.65%
Dec-05-22 07:30AM	Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance (GlobeNewswire) -5.43%
Nov-18-22 12:00PM	Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why (Zacks)
Nov-14-22 07:30AM	Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Oct-25-22 08:00AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent (GlobeNewswire)

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fraser Craig	President and CEO	Oct 08 '24	Buy	0.91	5,431	4,942	8,638	Oct 09 07:46 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WINT

Windtree Therapeutics Inc

Upgrade your FINVIZ experience